Advertisement

Cytopenias in Transplant Patients

  • Maura BarryEmail author
  • Sunandana Chandra
  • Kenneth B. Hymes
Chapter

Abstract

Anemia, leukopenia, thrombocytopenia, as well as pancytopenias can be seen following solid organ transplant. Varying patterns of cytopenia can be seen based on the drugs used in the posttransplant period, infections encountered by the individual, as well as the individual’s immune response and bone marrow function. The chapter discusses the main causes of anemia, leukopenia/neutropenia, and thrombocytopenia. The differential diagnosis for anemia after solid organ transplant includes hemolysis, drug toxicities, iron deficiency, infection, posttransplant lymphoproliferative disorder, graft-vs.-host disease, and hemophagocytic syndrome. Etiologies for leukopenia and neutropenia include drug toxicities and infection, and etiologies for thrombocytopenia include drug toxicities, infections, autoimmune events such as immune thrombocytopenic purpura, and underlying causes such as persistent portal hypertension and splenomegaly.

Keywords

Cytopenia Anemia Thrombocytopenia Leukopenia Neutropenia Pancytopenia 

References

  1. 1.
    Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant. 2003;3:835–45.PubMedCrossRefGoogle Scholar
  2. 2.
    Yorgin PD, Scandling JD, Belson A, Sanchez J, Alexander SR, Andreoni KA. Late post-transplant anemia in adult renal transplant recipients. Am J Transplant. 2002;2:429–35.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Kolonko A, Pinocy-Mandok J, Kocierz M, et al. Anemia and erythrocytosis after kidney transplantation: a 5 year graft function and survival analysis. Transplant Proc. 2009;8:3046–51.CrossRefGoogle Scholar
  4. 4.
    Przybylowski P, Malyszko J, Malyszko J. Anemia is a predictor of outcome in heart transplant recipients. Transplant Proc. 2009;41:322–3231.Google Scholar
  5. 5.
    Taegtmeyer AB, Rogers P, Breen JB, Barton PJ, Banner NR, Yacoub MH. The effects of pre- and post-transplant anemia on 1-year survival after cardiac transplantation. J Heart Lung Transplant. 2008;27:394–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Yazer MH, Triulzi DJ. Immune hemolysis following ABO-mismatched stem cell or solid organ transplantation. Curr Opin Hematol. 2007;14:664–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Audet M, Panaro F, Piardi T, et al. Passenger lymphocyte syndrome and liver transplantation. Clin Dev Immunol. 2009;2008:715769.CrossRefGoogle Scholar
  8. 8.
    Shortt J, Westall GP, Roxby D. A ‘dangerous’ group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies. Am J Transplant. 2008;8:711–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Seltsam A, Hell A, Heymann G, Salama A. Donor derived alloantibodies and passenger lymphocyte syndrome in two of four patients who received different organs from the same donor. Transfusion. 2001;41:365–70.PubMedCrossRefGoogle Scholar
  10. 10.
    Salerno CT, Burdine J, Perry EH, Kshettry VR, Hertz MI, Bolman IIIR. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation. 1998;65:261–4.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Panaro F, DeChristopher PJ, Rondelli D. Severe hemolytic anemia due to passenger lymphocytes after living related bowel transplant. Clin Transpl. 2004;18:332–5.CrossRefGoogle Scholar
  12. 12.
    Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004;15:1347–52.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Imoagene-Oyedeji AE, Rosas SE, Doyle AM, Goral S, Bloom RD. Posttransplantation anemia at 12 months in kidney recipients treated with mycophenolate mofetil: risk factors and implications for mortality. J Am Soc Nephrol. 2006;17:3240–7.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4:2001–6.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Pratap B, Abraham G, Srinivas CN, Bhaskar S. Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus. Saudi J Kidney Dis Transpl. 2007;18:609–12.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Go O, Naqvi A, Tan A, Amzuta I, Lenox R. The spectrum of thrombotic thrombocytopenic purpura: a clinicopathologic demonstration of tacrolimus-induced thrombotic thrombocytopenic purpura in a lung transplant patient. South Med J. 2008;101:744–7.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Saito M, Satoh S, Kagaya H, et al. Thrombotic microangiopathy developing in early stage after renal transplantation with a high trough level of tacrolimus. Clin Exp Nephrol. 2008;12:312–5.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Maheshwari A, Mishra R, Thuluvath PJ. Post-liver transplant anemia: etiology and management. Liver Transpl. 2004;10:165–73.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Nosari A, Marbello L, De Carlis LG, et al. Bone marrow hypoplasia complicating tacrolimus (FK506) therapy. Int J Hematol. 2004;79:130–2.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Engelen W, Verpooten GA, Van der Planken M, Helbert MF, Bosmans JL, De Broe ME. Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients. Clin Nephrol. 2003;60:119–24.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Naik PM, Lyon GM 3rd, Ramirez A, et al. Dapsone-induced hemolytic anemia in lung allograft recipients. J Heart Lung Transplant. 2008;27:1198–202.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine. 2004;83:265–73.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Dunford LM, Roy DM, Hahn TE, et al. Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:241–2.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Balbi E, Leal CR, Pacheco-Moreira LF, et al. Treatment for recurrent hepatitis C virus infection after liver transplantation. Transplant Proc. 2009;41:891–4.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–9.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Ar MC, Ozbalak M, Tuzuner N, et al. Severe bone marrow failure due to valganciclovir overdose after renal transplantation from cadaveric donors: four consecutive cases. Transplant Proc. 2009;41:1648–53.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Elimelakh M, Dayton V, Park KS, et al. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab pancreas transplant recipients. Haematologica. 2007;92:1029–36.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Mix TC, Kazmi W, Khan S, et al. Anemia: a continuing problem following kidney transplantation. Am J Transplant. 2003;3:1426–33.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Smith EP. Hematologic disorders after solid organ transplantation. Am Soc Hematol Am Soc Hematol Educ Program. 2010;2010:281–6.CrossRefGoogle Scholar
  30. 30.
    Park JB, Kim DJ, Woo SY, et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients – a prospective study. Transpl Int. 2009;22:455–62.CrossRefGoogle Scholar
  31. 31.
    Florea AV, Ionescu DN, Melhem MF. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med. 2007;131:799–804.Google Scholar
  32. 32.
    Shekar K, Hopkins PM, Kermeen FD, Dunning JJ, McNeil KD. Unexplained chronic anemia and leukopenia in lung transplant recipients secondary to parvovirus B19 infection. J Heart Lung Transplant. 2008;27:808–11.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Marinella MA. Hematologic abnormalities following renal transplantation. Int Urol Nephrol. 2010;42:151–64.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS guidelines. Br J Haematol. 2010;149:693–705.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Kato T, Yazawa K, Madono K, Saito J, Hosomi M, Itoh K. Acute graft-vs-host disease in kidney transplantation: case report and review of literature. Transplant Proc. 2009;41:3949–52.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Lo MM, Mo JQ, Dixon BP, Czech KA. Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients. Am J Transplant. 2010;10:687–91.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–51.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Hartmann EL, Gatesman M, Roskopf-Somerville J, Stratta R, Farney A, Sundberg A. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transpl. 2008;22:822–8.CrossRefGoogle Scholar
  39. 39.
    Dewit O, Moreels T, Baert F, et al. Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients. Clin Biochem. 2011;44:1062–6.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc. 2004;36:703–4.PubMedCrossRefGoogle Scholar
  41. 41.
    The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029–37.CrossRefGoogle Scholar
  42. 42.
    Knoll GA, MacDonald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003;14:2381–6.PubMedCrossRefGoogle Scholar
  43. 43.
    Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant then CMV and EBV. Transplantation. 2008;86:1327–39.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Thomas LD, Hongo I, Bloch KC, Tang YW, Dummer S. Human ehrlichiosis in transplant patients. Am J Transplant. 2007;7:1641–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Arakawa Y, Matsui A, Sasaki N, Nakayama T. Agranulocytosis and thrombocytopenic purpura following measles infection in a living-related orthotopic liver transplantation recipient. Acta Paediatr Jpn. 1997;39:226–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Wiwanitkit V. Dengue infection in kidney transplant patients: an appraisal on clinical manifestation. Iran J Kidney Dis. 2010;4:168.PubMedGoogle Scholar
  47. 47.
    Eid AJ, Brown RA, Patel R, Razonable RR. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis. 2006;43:40–8.CrossRefGoogle Scholar
  48. 48.
    Karakus S, Arin BE, Arat Z, Karakayali H, Haberal M. Impact of hepatitis serology on development of leukopenia after solid organ transplantation. Transplant Proc. 2008;40:199–201.PubMedCrossRefGoogle Scholar
  49. 49.
    Razeghi E, Hadadi A, Mansor-Kiaei M, Molavi M, Khashayar P, Pourmand G. Clinical manifestation, laboratory findings, and the response of treatment in kidney transplant recipients with CMV infection. Transplant Proc. 2007;39:993–6.PubMedCrossRefGoogle Scholar
  50. 50.
    Simmons P, Kaushansky K, Torok-Storb B. Mechanisms of cytomegalovirus-mediated myelosuppression: perturbation of stromal cell function versus direct infection of myeloid cells. Proc Natl Acad Sci U S A. 1990;87:1386–90.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Kute VB, Vanikar AV, Shah PR, et al. Post-renal transplant cytomegalovirus infection: study of risk factors. Transplant Proc. 2012;44:706–9.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Cooke ME, Potena L, Luikart H, Valantine HA. Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients: impact of acute disease versus subclinical infection. Transplantation. 2006;82:1419–24.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Rane S, Nada R, Minz M, Sakhuja V, Joshi K. Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients. Transplant Proc. 2012;44:713–6.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    De Keyzer K, Van Laecke S, Peeters P, Vanholder R. De novo thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss. Am J Nephrol. 2010;32:491–6.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23–35.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Ramasubbu K, Mullick T, Koo A, et al. Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review. Transpl Infect Dis. 2003;5:98–103.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Hachem RR, Yusen RD, Chakinala MM, Aloush AA, Patterson GA, Trulock EP. Thrombotic microangiopathy after lung transplantation. Transplantation. 2006;81:57–63.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation. 2008;86:1327–39.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Caires RA, Marques IDB, Repizo LP, et al. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival. Transplant Proc. 2012;44:2388–90.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Fouad YM. Chronic hepatitis C-associated thrombocytopenia: aetiology and management. Trop Gastroenterol. 2013;34:58–67.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Smith EP. Hematologic disorders after solid organ transplantation. ASH Educ Program Book. 2010;2010:281–6.Google Scholar
  62. 62.
    Devadoss CW, Vijaya VM, Mahesh E, Venkataramana SR, Girish MS. Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation. J Clin Diagn Res. 2012;6:1786–8.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Boyer NL, Niven A, Edelman J. Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient. BMJ Case Rep. 2013;2013:bcr2012007351.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Nwaba A, MacQuillan G, Adams LA, et al. Tacrolimus-induced thrombotic microangiopathy in orthotopic liver transplant patients: case series of four patients. Intern Med J. 2013;43:328–33.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Fortin MC, Raymond MA, Madore F, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant. 2004;4:946–52.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Minson Q, Gentry CA. Analysis of linezolid-associated hematologic toxicities in a large veterans affairs medical center. Pharmacotherapy. 2010;30:895–903.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother. 2003;37:517–20.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    El-Khoury J, Fishman JA. Linezolid in the treatment of vancomycin-resistant enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. Transpl Infect Dis. 2003;5:121–5.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Radunz S, Juntermanns B, Kaiser GM, et al. Efficacy and safety of linezolid in liver transplant patients. Transpl Infect Dis. 2011;13:353–8.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 2002;34:695–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4:7.Google Scholar
  72. 72.
    Bachmann R, Bachmann J, Lange J, Nadalin S, Konigsrainer A, Ladurner R. Incidence of heparin-induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients: a retrospective cohort analysis. J Surg Res. 2014;186:429–35.PubMedCrossRefGoogle Scholar
  73. 73.
    Kaneko J, Sugawara Y, Tamura S, Togashi J, Matsui Y, Makuuchi M. Heparin-induced thrombocytopenia after liver transplantation. Transplant Proc. 2008;40:1518–21.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Dracopoulos S, Vougas V, Kassimatis TI, Theodoridis T, Ali ME, Apostolou T. Heparin-induced thrombocytopenia type II: a serious hazard in preemptive renal transplantation: a case report. Transplant Proc. 2007;39:3481–4.PubMedCrossRefGoogle Scholar
  75. 75.
    Muzaffar M, Li X, Ratnam S. Successful preemptive renal retransplantation in a patient with previous acute graft loss secondary to HIT type II: a case report and review of literature. Int Urol Nephrol. 2012;44:991–4.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Chaturvedi S, Kohli R, McCrae K. Over-testing for heparin induced thrombocytopenia in hospitalized patients. J Thromb Thrombolysis. 2015;40(1):12–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Lugao Rdos S, Motta MP, de Azevedo MF, et al. Immune thrombocytopenic purpura induced by intestinal tuberculosis in a liver transplant recipient. World J Gastroenterol. 2014;20:8304–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Einollahi B. Renal transplantation and idiopathic thrombocytopenic purpura: two case reports. Transplant Proc. 2009;41:2923.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Taylor RM, Bockenstedt P, Su GL, Marrero JA, Pellitier SM, Fontana RJ. Immune thrombocytopenic Purpura following liver transplantation: a case series and review of the literature. Liver Tranplant. 2006;12:11.Google Scholar
  80. 80.
    Pereboom IT, de Boer MT, Haagsma EB, van der Heide F, Porcelijn L, Lisman T, Porte RJ. Transmission of idiopathic thrombocytopenic purpura during orthotopic liver transplantation. Transplant Int. 2010;23:3.CrossRefGoogle Scholar
  81. 81.
    Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol. 2013;161:706–14.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Yang YJ, Yun GW, Song IC, et al. Clinical implications of elevated antiphospholipid antibodies in adult patients with primary immune thrombocytopenia. Korean J Intern Med. 2011;26:449–54.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Chatzipetrou MA, Tsaroucha AK, Weppler D, et al. Thrombocytopenia after liver transplantation. Transplantation. 1999;67:702–6.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Plevak DJ, Halma GA, Forstrom LA, et al. Thrombocytopenia after liver transplantation. Transplant Proc. 1988;20:630–3.PubMedGoogle Scholar
  85. 85.
    Pham PT, Danovitch GM, Wilkinson AH, et al. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002;74:1077–80.PubMedCrossRefGoogle Scholar
  86. 86.
    Liesveld JL, Phillips GL 2nd, Becker M, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant. 2013;19:1745–52.PubMedCrossRefGoogle Scholar
  87. 87.
    Minowa K, Arai K, Kasahara M, et al. Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis. Pediatr Transplant. 2014;18:E212–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Maura Barry
    • 1
    Email author
  • Sunandana Chandra
    • 2
  • Kenneth B. Hymes
    • 3
  1. 1.Division of Hematology and OncologyLarner College of Medicine at the University of Vermont, University of Vermont Medical CenterBurlingtonUSA
  2. 2.Division of Hematology and OncologyNorthwestern University Feinberg School of MedicineChicagoUSA
  3. 3.Hematology, Coagulation, and Medical Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone HealthNew YorkUSA

Personalised recommendations